This is the culmination of over 60 million inNIH/NIDCR research grants over the last 8 years, and has been reported in the OCF in the news section some time ago. It will be available for sale, having just received its FDA approval 10 days ago, by the end of June. It is NOT specific at this time for cancer, though it does find it very accurately along with a host of other disease states in cells. So while this finds things, it is the lack of specificity that is the issue. That does not make it a less valuable device, it means that once something is found there is an interpretation issue on the part of the clinician that has to take place.

Brian, stage 4 oral cancer survivor. OCF Founder and Director. The first responsibility of a leader is to define reality. The last is to say thank you. In between, the leader is a servant.